Speakers

Expand/Collapse

Alexander Savchenko
IHC/ISH and Digital Pathology Diagnostic Group Director
Novartis

Martin J Schnermann
Investigator
National Cancer Institute

Day One

Wednesday June 24 2020

12:30 pm | Interactive Panel Discussion

11:50 am | Chemical Tools for Dynamic & Multicolor Optical Imaging In Vivo

Mohan Singh
Investigator: Imaging Mass Cytometry
GlaxoSmithKline

Day One

Wednesday June 24 2020

4:00 pm | Evaluating Drug Response From Data Analysis to Advance Candidate Development

Mark Pagel
Professor, Department of Cancer Systems Imaging Department of Cancer Systems Imaging, Division of Diagnostic Imaging
MD Anderson Cancer Center

Day One

Wednesday June 24 2020

3:00 pm | Panel Discussion – The Future of Digital Pathology: Challenging Traditional Standard of Care Guidelines with AI Data

2:00 pm | Multimodal Applications to Understand the Tumor Microenvironment

Cleopatra Kozlowski
Senior Scientist
Genentech

Day One

Wednesday June 24 2020

3:00 pm | Panel Discussion – The Future of Digital Pathology: Challenging Traditional Standard of Care Guidelines with AI Data

2:40 pm | An AI-Powered Digital Pathology Toolbox to Advance Oncology Biomarker Development

James Basilion
Director, Case Center for Imaging Research,
Case Western Reserve University

John Waterton
Professor - Translational Imaging
University of Manchester

Day One

Wednesday June 24 2020

9:40 am | Why Imaging Biomarkers Fail?

10:30 am | Interactive Panel Discussion – Developing an Imaging Biomarker Strategy

Mohammad Rashidian
Member of the Faculty
Dana-Farber Cancer Institute

Day One

Wednesday June 24 2020

4:40 pm | Imaging the Tumor Environment

Alexander Adler
Scientist
Regeneron Pharmaceuticals

Day One

Wednesday June 24 2020

12:30 pm | Interactive Panel Discussion

11:30 am | Assessing the Effects of VEGF Blockade in Preclinical Tumor Models Using Non-Invasive Imaging Modalities

Mike Farwell
Assistant Professor
University of Pennsylvania

Peter Choyke
Program Director Molecular Imaging
NCI

Day One

Wednesday June 24 2020

10:30 am | Interactive Panel Discussion – Developing an Imaging Biomarker Strategy

9:00 am | Building on the Key Relationship: Setting the Goals Between Industry & Academic Imaging

Khalid Shah
Vice Chair of Research, Brigham and Women's Hospital Director, Center for Stem Cell Therapeutics and Imaging
Brigham & Women's Hospital

Day One

Wednesday June 24 2020

4:20 pm | Multimodal Imaging for Translating Stem Cell-Based Therapy into the Clinic

Gabriela Kramer-Marek
Team Leader, Preclinical Molecular Imaging
Institute of Cancer Research

Day One

Wednesday June 24 2020

10:30 am | Interactive Panel Discussion – Developing an Imaging Biomarker Strategy

9:20 am | Development of Molecularly Targeted Imaging Agents to Advance Cancer Stratification & Treatment

David Leung
Medical Director, Oncology Imaging
Bristol-Myers Squibb

Day One

Wednesday June 24 2020

3:00 pm | Panel Discussion – The Future of Digital Pathology: Challenging Traditional Standard of Care Guidelines with AI Data

2:20 pm | Multimodal Imaging for Improved Drug Efficacy Understanding

Vaishali Shinde
Associate Director - Clinical Biomarker Innovation & Development, Quantitative Translational Sciences
Takeda

Day One

Wednesday June 24 2020

12:30 pm | Interactive Panel Discussion

12:10 pm | Bridging the Preclinical-Clinical Gap

Xiaoyou Ying
Head of Bioimaging US, Translational In vivo Models, Global Research Platform
Sanofi

Chaitanya Divgi
VP Clinical Development & CMO
Tomopath

Chaitanya Divgi is a Nuclear Oncologist with over 30 years of academic experience in the United States developing radiopharmaceuticals for cancer imaging and therapy. Chaitanya’s research has focused particularly on proteins that recognize cancer cell surface antigens. His research has investigated radioimmunotherapy with a variety of nuclides and antibodies against solid tumors as well as hematologic malignancies. He is a regular reviewer in journalsincluding JAMA Oncology, Cancer Research and Clinical Cancer Research, Journal of Clinical Oncology, Journal of Nuclear Medicine and Molecular Imaging, and is a member of several ad-hoc review panels at the National Institutes of Health as well as Canadian and European grant review panels. He has successfully steered numerous FDA (Investigational) New Drug Applications (INDs and NDAs). Dr. Divgi was instrumental in developing the molecular imaging and therapy program in Nuclear Medicine at Memorial Sloan-Kettering Cancer Center, New York, during his 20+ years there on the faculty of Radiology (Nuclear Medicine) and Medicine (Immunology). Dr. Divgi carried out the first clinical immunoPET study (using 124I-girentuximab), and is a leader in the assessment of imaging (multi-modality and modality-agnostic) in the development of cancer therapeutics. He left as Professor of Medicine (Immunology) and Radiology (Nuclear Medicine) in May 2006 and went to the University of Pennsylvania as Chief of Nuclear Medicine and Clinical Molecular Imaging and Professor in the Departments of Radiology and Radiation Oncology (2006-11). At Penn Dr. Divgi acquired the first time-of-flight PET/CT and also obtained a NCRR high-end instrumentation grant for an isotope production cyclotron, the centerpiece of a robust, state- of-the-art radiopharmaceutical production facility. Subsequently (2011-16), Chaitanya went to Columbia University as Vice-Chair, Radiology Research, Columbia University Medical College, and Chair, Radioactive Drug Research Committee, with a joint appointment in the Department of BioMedical Engineering at the School of Engineering and Applied Sciences, and co-Principal Investigator of the Coulter program to identify promising medical devices and drugs. There he rejuvenated the PET/CT program, instituting a comprehensive IND radiopharmaceutical production center that has successfully obtained approval for numerous agents used in neuroscience and oncology research throughout Columbia. In 2016 he left academia to consult with multiple biotech and pharmaceutical companies and imaging contract research organizations.

Day One

Wednesday June 24 2020

10:10 am | Pitfalls and Promises in the Development of Imaging Biomarkers for Drug Development in Oncology

10:30 am | Interactive Panel Discussion – Developing an Imaging Biomarker Strategy